Navigation Links
Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
Date:5/28/2008

rienced a MST of 10.5 months compared with 8.7 months for those patients who received doxorubicin (unadjusted log rank p=0.016).

"I am pleased that we have reached this important milestone for both Alfacell and ONCONASE," said Kuslima Shogen, Alfacell's chief executive officer. "We are deeply appreciative of the cancer patients and clinical investigators who participated in this important trial."

Based on the preliminary statistical analysis of the data, Alfacell will continue with the planned submission of the remaining components of the ONCONASE rolling NDA. Pending completion of the analysis of the data and further discussions with the FDA, the company currently estimates that the NDA submission will be completed by the end of calendar year 2008.

Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of Par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong, USP Pharma Spolka Z.O.O., an affiliate of US Pharmacia, for Eastern Europe, and GENESIS Pharma, S.A. for Southeastern Europe.

ONCONASE has been granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

Conference Call & Webcast

Alfacell will host a conference call and Webcast to discuss the preliminary results at 8:30 a.m. EDT on Thursday, May 29. To participate in the live conference call, U.S. residents may dial 1-877-407-9205, and international callers may dial 1-201-689-8054. A replay of the call will be available until June 5. To access the replay, U.S. residents may dial 1-877-660-6853, and international callers may dial 1-201-612-7415 and enter account number 286 and conference ID number 284844. A live Webcast and replay of the conference call will be available on Al
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
7. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
8. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
9. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
10. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
11. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 /CNW/ - Covalon Technologies Ltd. (the ... announces the following financial results for its third quarter of ... 30, 2014: , Revenue of $1,291,378, a 13% ... , Net loss for the quarter of $240,156 compared to ... prior year For the nine months ended ...
(Date:8/27/2014)... 27, 2014  After the February 2014 launch of ... solution for medical practices and management companies, Prime ... new software. "The feedback has been great," ... "The sheer number of demos and new sign-ups is ... for these types of software features." ...
(Date:8/27/2014)... , Aug. 27, 2014 Sinovac Biotech Ltd. (NASDAQ: ... China , today announced the results of the Company,s ... 2014 in Beijing , PRC. The required quorum, ... The Company,s shareholders approved the following proposals:  ... Lam Lo , Simon Anderson , Kenneth Lee ...
Breaking Medicine Technology:Covalon Announces Third Quarter Results 2Covalon Announces Third Quarter Results 3Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 2Medical Software Company, Prime Clinical Systems, Sees Excellent Response to their Workers' Compensation Solutions 3Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2
... derivative compound series,show highly selective PI3K-inhibition which ... 16, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris,Inc. , ... on,endocrine therapy and oncology, today presented an ... pyridopyrazine derivatives,with high selectivity for PI3K inhibition, ...
... With Improved Potential to,Battle Their Disease, PASADENA, ... Inc., a majority-owned subsidiary of Arrowhead,Research Corporation ... will be featured in a poster presentation ... (AACR) Annual,Meeting. In particular, this poster includes ...
Cached Medicine Technology:AEterna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 3Poster on Cyclosert Drug Delivery Presented at AACR Meeting 2Poster on Cyclosert Drug Delivery Presented at AACR Meeting 3Poster on Cyclosert Drug Delivery Presented at AACR Meeting 4
(Date:8/27/2014)... PA (PRWEB) August 27, 2014 What’s ... of this year’s 87th Annual Scripps National Spelling Bee? ... for a tour of internationally renowned Wills Eye Hospital.     ... like to be an ophthalmologist one day. , Wills ... eye surgery and the latest hi-tech visual diagnostic testing. ...
(Date:8/27/2014)... NC. SonaCare Medical, LLC, the global leader in ... 15 HIFU devices over the past twelve months pointing ... company’s ablation technology. , “It is truly exciting ... the past year, especially since we are now heading ... active sales period,” says Mike Klein, CEO of SonaCare ...
(Date:8/27/2014)... -- A new study finds that continuous positive airway ... sleep apnea. CPAP is widely used to treat ... which the airway relaxes and narrows during sleep, causing ... daytime drowsiness. CPAP keeps the airway open ... nose via a mask that is worn during sleep. ...
(Date:8/27/2014)... (HealthDay News) -- Overconfident people are better at convincing ... and therefore are more likely to get promotions and ... researchers added that these "self-deceived" people are also more ... greater risks. And finally, people who underestimate themselves ... to the British researchers. Their findings were published Aug. ...
(Date:8/27/2014)... each receive $100,000 in funding to launch pilot programs ... for patients served by community health centers. The program ... and is part of the group,s effort to reach ... over receiving regular screening for colorectal cancer by 2018. ... are: Port Royal, South Carolina; New Haven, Connecticut; and ...
Breaking Medicine News(10 mins):Health News:Scripps National Spelling Bee Co-Champion and Aspiring Ophthalmologist Coming to Wills Eye Hospital in Philadelphia 2Health News:SonaCare Medical Announces Twelve Months Sales Results of Fifteen HIFU Devices 2Health News:Sleep Apnea Treatment Helps Seniors, Study Finds 2Health News:Overconfident Folks May Blind Others to Their Real Abilities 2Health News:Pilot program aims to improve cancer screening, specialty care in community health centers 2Health News:Pilot program aims to improve cancer screening, specialty care in community health centers 3
... -- Poor memory and problems with other mental skills may be ... suggests. Researchers gave a word recall memory test to 17,851 ... to measure the brain,s executive functioning skills. The participants, who were ... a stroke, were then contacted twice a year for up to ...
... source of cocaine, is speeding up destruction of rainforests ... and animal diversity, scientists are reporting in a new ... for establishing larger protected areas to help preserve biodiversity, ... . Liliana M. Dvalos and colleagues note ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, Feb. ... necessary in women with early breast cancer who also undergo a ... in the Feb. 9 issue of the Journal of the ... sentinel nodes -- those lymph nodes to which the cancer spreads ...
... study from Utrecht and Cambridge Universities has for the ... the tongue in volunteers negatively affects a person,s ability ... findings are published this week in the journal ... addition, the effects of testosterone administration are predicted by ...
... University medical device startup that has developed a system ... closing the beating heart during cardiac surgery has received ... the Georgia Tech/Emory technology and will further develop the ... procedure required for delivering therapeutic devices to the heart ...
... -- An injection of local anesthetic can be made ... researchers report. They reviewed 18 studies that included ... injections led to a "clinically meaningful reduction in pain," ... not; whether the shot was administered subcutaneously (under the ...
Cached Medicine News:Health News:Could Poor Memory Signal Raised Stroke Risk? 2Health News:Cocaine production increases destruction of Colombia's rainforests 2Health News:Removing Many Lymph Nodes in Early Breast Cancer Not Always Needed: Study 2Health News:Removing Many Lymph Nodes in Early Breast Cancer Not Always Needed: Study 3Health News:Extra testosterone reduces your empathy 2Health News:Apica Cardiovascular receives $5.1 million investment for improved heart surgery system 2Health News:Apica Cardiovascular receives $5.1 million investment for improved heart surgery system 3
... assembly. Superb Bi-Polar range of ... Superior pull-out and lever-out strength. ... 44, 48, 52, 56, 60 ... component for all shells. Increased ...
... index. A/P and lateral fins with holes ... medial hole, humeral / glenoid diametral curvature ... textured proximal surface to provide enhanced proximal ... cement, six stem sizes, fifteen head sizes ...
...
...
Medicine Products: